Cervical Spondylotic Myelopathy Pain (Investigational Adjunct)

Investigational adjunct for paraspinal pain in mild cervical spondylotic myelopathy; surgical decompression remains evidence-based when myelopathic signs progress; conservative management for mild non-progressive disease.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?: Not FDA-cleared for cervical spondylotic myelopathy pain. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
¿Qué evidencia existe?: Tier C (investigational). Cervical spondylotic myelopathy is spinal cord compression and is a primarily surgical disease. Evidence-based first-line management is neurosurgical evaluation; patients with progressive myelopathy benefit from decompressive surgery (anterior cervical decompression and fusion, posterior decompression, or laminoplasty). Conservative care alone is reasonable only for very mild stable disease. Pain may be managed with PT and neuropathic-pain medications, but the underlying compression is structural.
Riesgos principales: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Cervical placement near important vessels and nerves
Delaying urgent surgical decompression in progressive myelopathy can result in permanent spinal cord damage
Mistaking transient symptom relief for disease improvement
Quién no debería considerar esto: Patients with progressive myelopathy who have not had neurosurgical evaluation
Patients with significant gait disturbance, hand clumsiness, or hyperreflexia (these are surgical indications)
Patients with severe cord compression on MRI
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
Qué preguntar a su clínico: Have I had a neurosurgical opinion on whether surgical decompression is indicated?
What is my modified Japanese Orthopaedic Association (mJOA) score, and is it progressing?
How will progression of myelopathy be detected during the leech course?
What is the bleeding-control plan in the neck?
What is the published evidence base for leeches in CSM specifically?
What is the plan if my symptoms worsen rather than improve?
Cuándo buscar atención urgente: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
New or progressive arm or leg weakness, gait change, or hand dexterity loss
New bladder or bowel changes
Severe new neck pain with neurologic symptoms

Qué NO significa esto

It does not mean leech therapy is FDA-cleared for myelopathy — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace surgical decompression for progressive myelopathy.
It does not address the structural cord compression driving the disease.
It does not prevent permanent spinal cord injury if disease progresses untreated.
It does not have controlled-trial evidence in CSM.

Referencias cruzadas de seguridad

Clinical Profile

Category: neurological
ICD-10: M47.12, M50.00, M50.020, G99.2
Safety tier: high

Evidence Summary

Cervical spondylotic myelopathy is the most common cause of spinal cord dysfunction in adults over 55, producing gait imbalance, hand clumsiness, hyperreflexia, and (later) bowel/bladder dysfunction. Evidence-based management of progressive or moderate-to-severe myelopathy is anterior cervical decompression and fusion or laminoplasty; mild non-progressive disease may be managed conservatively with NSAIDs, physical therapy, soft cervical collar during flares, and serial neurologic examination. No published controlled trials of hirudotherapy exist for cervical myelopathy. Paraspinal placement may transiently reduce muscle spasm and local pain but does not address spinal canal narrowing and cannot prevent neurologic progression. Any progressive myelopathic signs require urgent surgical referral.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Progressive myelopathic signs — urgent surgical referral required
Severe canal stenosis with cord signal change on MRI
Recent cervical spine surgery or instrumentation
Untreated cervical instability or fracture
Anticoagulation for cardiovascular indication

Related Conditions

Cervical Radiculopathy

Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.

Lumbar Radiculopathy (Sciatica)

Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.

Migraine

Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.

Tension-Type Headache

Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.